CA2748251C — Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
Assigned to Sumitomo Pharma Co Ltd · Expires 2016-08-02 · 10y expired
What this patent protects
A compound represented by formula (1) (see formula 1) or a pharmacologically acceptable salt thereof is provided. (In formula (1), R1 is a hydrogen atom, etc.; L is a single bond, -O-, etc.; R2 is phenyl, etc.; X is a carbon atom or a nitrogen atom; and R3, R4, R5a, R5b, R6, and …
USPTO Abstract
A compound represented by formula (1) (see formula 1) or a pharmacologically acceptable salt thereof is provided. (In formula (1), R1 is a hydrogen atom, etc.; L is a single bond, -O-, etc.; R2 is phenyl, etc.; X is a carbon atom or a nitrogen atom; and R3, R4, R5a, R5b, R6, and R7 each is a substituted or unsubstituted alkyl, etc.) Compounds of the invention may be used for inhibition of SNS.
Drugs covered by this patent
- Mulpleta (LUSUTROMBOPAG) · Vancocin Italia
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.